<DOC>
	<DOCNO>NCT02614898</DOCNO>
	<brief_summary>This prospective , open-label study patient randomization . Treatment atypical hemolytic uremic syndrome ( aHUS ) remain observational discretion treat physician . The purpose study assess disease manifestation complement mediate thrombotic microangiopathy ( TMA ) potential clinical predictor disease manifestation progression patient aHUS without eculizumab treatment clinical setting .</brief_summary>
	<brief_title>Eval . Potential Predictors Disease Progression Patients With aHUS Including Genetics , Biomarkers Treatment</brief_title>
	<detailed_description />
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Hemolytic-Uremic Syndrome</mesh_term>
	<mesh_term>Atypical Hemolytic Uremic Syndrome</mesh_term>
	<criteria>1 . Currently receive eculizumab treatment M11001 aHUS Registry 2 . Two normal platelet count least 4 week apart 3 . Two normal LDH level least 4 week apart 4 . Willing , commit , able return ALL clinic visit complete studyrelated procedure 5 . Patient patient 's parent/legal guardian must willing able give write informed consent . Patient ( minor ) must willing give write informed assent ( applicable determine central Institutional Review Boards/Independent Ethics Committees ) 1 . Any prior eculizumab treatment discontinuation 2 . On chronic dialysis ( define â‰¥3 month dialysis ) 3 . Currently participate another complement inhibitor trial 4 . Life expectancy &lt; 6 month 5 . Patient patient 's parent/legal guardian unable give write informed consent . Patient ( minor ) unable give write informed assent ( applicable determine central Institutional Review Boards/Independent Ethics Committees )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>